# Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

> **NCT06074107** · PHASE2 · UNKNOWN · sponsor: **BeBetter Med Inc** · enrollment: 128 (estimated)

## Conditions studied

- Relapsed or Refractory Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** BEBT-908 for injection

## Key facts

- **NCT ID:** NCT06074107
- **Lead sponsor:** BeBetter Med Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-12
- **Primary completion:** 2023-12-20
- **Final completion:** 2023-12-25
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06074107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06074107, "Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06074107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*